Loading…
RDHL
RedHill Biopharma Ltd.
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 757468301
$0.66+6.61%Price as of Aug 29, 18:39 UTC · updated once a day, after the close
Key metrics
- Market cap
- $4.02M
- P/E
- —
- Forward P/E
- 22.0x
- P/B
- 0.8x
- Dividend yield
- —
- Payout
- —
- EPS
- $0.00
- ROE
- —
- Profit margin
- -150.00%
- Revenue growth
- —
- Beta
- 4.90
- 52-week high
- $2.79
- 52-week low
- $0.57
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -100.0% over 5Y.
today you would have $0.11▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.03 | $6.21 | $36.50 | $140.00 | |
| P/E | — | — | — | 0.4x | — |
| P/S | — | 183395.0x | — | — | 2111.2x |
| P/B | — | 12289.4x | — | 138835.0x | — |
| EPS | — | $0.00 |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MBIOMustang Bio Inc | $0.54 | — | 0.5x | — | -58.12% | $4.07M |
| TCRTAlaunos Therapeutics, Inc. | $1.61 | — | 3.0x | — | -185.95% | $4.08M |
| ISPCiSpecimen Inc. | $1.54 | — | 0.1x | — | -968.47% | $3.88M |
| REVBRevelation Biosciences Inc | $1.05 |
About the company
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
- 13
- Tel Aviv-Yafo, Israel
Company description provided by Yahoo Finance.